United States
How can life sciences companies looking to go public position themselves for success? It’s all about setting the stage early on.
Informa Connect’s Finance and Accounting for Bioscience Companies East will be a HYBRID event, combining live and digital.
Understanding the impact and the significance of the upcoming changes on Life Sciences companies and tax policies.
We able to gather again in person, at the Hyatt Regency in New Brunswick, N.J. for the 26th annual Medicaid Drug Rebate Program conference
What can life sciences businesses do to ensure data protection, especially with their third parties? Get key cybersecurity considerations.
Learn how outsourcing can help life sciences organization establish a strong foundation for current and sustained success.
Companies abandoning plans for IPO or SPAC transactions should consider the deductibility of transaction costs and termination fees.
Whether pharma, biotech or medical device business, learn the five key questions you should consider now as you begin your IPO journey.
RSM’s life sciences industry insider shares key insights and benefits of conducting a third-party contract compliance audit.
Learn how life sciences companies leverage finance & accounting outsourcing to enhance the finance function and focus on core competencies.
Issues to consider when incorporating a partnership to benefit from the qualified small business stock exclusion
Third parties provide a vital business partnership for growing life sciences companies, but there are risks to consider.
Life sciences companies, learn how you can get the most out of your outsourcing relationships and keep your focus on the science
Build your foundation of understanding about the complexities of VAT and GST and the impact they can have on U.S. multinational businesses.
Cyberthreats are here to stay for life sciences companies, but staying a step ahead of the criminals can ensure the good guys win the day.
Hear perspectives from RSM about transfer pricing trends and planning opportunities for the life sciences industry.
Middle market biopharma companies face business challenges as they expand and launch new products. What are these issues and opportunities?
After 17 months of internal discussions, the German administration approved a draft bill to implement the EU Anti-Tax Avoidance Directives.
Life sciences companies are on a healthy fundraising pace. What’s predicted for investments and exits for the remainder of 2021?
Join our webcast to learn how cloud ERPs, like Oracle NetSuite, can support organizations navigating clinical and commercial contracts.